Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New (2018)
Complimentary CME Webinar!
Wednesday, September 12, 2018 | 7:00 - 8:00 p.m. ET
There is a growing need for urologists to be able to effectively manage CRPC. The AUA recently released its 2017 report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in this area. Additionally, the findings indicate that the AUA should continue to develop courses and educational materials specifically targeted at residents that covers the medical management of advanced prostate cancer.
The AUA has launched an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer (CRPC). Based on the documented need for additional education in this area, the AUA in collaboration with SUO has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
The 2018 series is comprised of a variety of activities, including two live forums, four live webinars, webcasts and podcasts. All activities are complimentary.
Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New is the third live webinar in a 4-part series of live webinars. Topics will include "Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents" and "Radionuclide Therapy and Bone Health".
Webinar #1: The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know - Wednesday, July 25, 2018, 7-8 p.m. ET
Webinar #2: Emerging Treatment of M0 CRPC: Update on the AUA/SUO Guidelines and Beyond - Wednesday, August 22, 2018, 7-8 p.m. ET
Webinar #3: Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New - Wednesday, September 12, 2018, 7-8 p.m. ET
Webinar #4: Sequencing of Chemotherapy and Immunotherapy in Advanced Prostate Cancer: Present and Future - Wednesday, October 17, 2018, 7-8 p.m. ET
This educational series is supported by independent educational grants from:
- Astellas and Pfizer Inc.
- Ferring Pharmaceuticals Inc.
- Genomic Health
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Sanofi Genzyme
- Tolmar Pharmaceuticals, Inc.
- Advanced practice providers
- This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer
At the conclusion of this activity, participants will be able to:
Practice Gap (Disease State)
- Discuss the molecular mechanisms and characterization of CRPC.
Practice Gap (Guidelines)
- Discuss specific recommendations within the AUA Clinical Practice Guidelines.
Practice Gap (Androgen Axis)
Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
Discuss new uses for androgen axis agents in M0 CRPC.
Practice Gap (Chemotherapy, Immunotherapy and Co-Morbidity)
Identify co-morbid states and recognize their impact on treatment options for mCRPC.
Discuss treatment sequencing.
Practice Gap (Bone Health and Radionuclide Therapy)
Integrate advances in bone health management into patient-specific care plans.
Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
Wednesday, September 12, 2018
7:00 - 7:05 p.m. Welcome - David F. Jarrard, MD
7:05 - 7:10 p.m. Pre-Test - David F. Jarrard, MD
7:10 - 7:30 p.m. Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents - Kristen Scarpato, MD
7:30 - 7:50 p.m. Radionuclide Therapy and Bone Health - Kelly L. Stratton, MD
7:50 - 8:00 p.m. Post-Test - David F. Jarrard, MD
Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New is the third live webinar in 4-part series of live webinars. It will be held on Wednesday, September 12 at 7:00 p.m. ET.
1) Click the "Register" tab.
2) If prompted, click “update your profile”. Otherwise, click “Take Course”.
3) Click "Participant Instructions" and then "Start". You will then be provided with full details on how to access the audio and web (video) components of the webinar.
This webinar will be conducted via Adobe Connect with a toll-free teleconference available for the audio component. Participants only need a standard web browser to participate. Please plan to join this session 15 minutes early to ensure that you are able to access the virtual classroom.
You may test your system ahead of time by clicking here.
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
Limit content to evidence with no recommendations
Introduction of a debate format with an unbiased moderator (point-counterpoint)
Inclusion of moderated panel discussion
Publication of a parallel or rebuttal article for an article that is felt to be biased
Limit equipment representatives to providing logistics and operation support only in procedural demonstration.
Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation